Sterling Capital Management
RAPP icon

Sterling Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Sterling Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.1K Buy
984
+843
+598% +$36.4K ﹤0.01% 1945
2026
Q2 		$5.88K Sell
141
-834
-86% -$30.7K ﹤0.01% 2526
2026
Q1 		$30.5K Sell
975
-665
-41% -$18.7K ﹤0.01% 1835
2025
Q4 		$49.8K Buy
1,640
+429
+35% +$11.9K ﹤0.01% 1804
2025
Q3 		$36K Buy
1,211
+737
+155% +$13.1K ﹤0.01% 1881
2025
Q2 		$5.39K Buy
474
+329
+227% +$3.49K ﹤0.01% 2464
2025
Q1 		$1.45K Buy
145
+2
+1% +$26 ﹤0.01% 2691
2024
Q4 		$2.54K Buy
143
+124
+653% +$2.75K ﹤0.01% 2713
2024
Q3 		$389 Buy
+19
New +$408 ﹤0.01% 2970

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Catalyst Private Wealth
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management's RAPP Position: Q3 2026 in Review

Sterling Capital Management increased its Rapport Therapeutics (RAPP) stake by 598% in Q3 2026, buying an estimated $36.4K and bringing the position to 984 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Sterling Capital Management first reported a position in RAPP in Q3 2024 and has held it in 9 quarters since. The position peaked at $49.8K in Q4 2025. 24 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Sterling Capital Management held 984 shares of Rapport Therapeutics worth $33.1K as of Q3 2026.
  • Sterling Capital Management bought 843 Rapport Therapeutics shares in Q3 2026, an estimated $36.4K.
  • Rapport Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1945 holding.
  • Sterling Capital Management first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Rapport Therapeutics position peaked at $49.8K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.